RxDoctor Payments Data

Maeghan Smith, NP

Family · China Grove, NCNPI 1871256743

Payments from drug & device makers

$11,673in general payments, 2019–2025

Across 724 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Bayer$833
  • GSK$673
  • Astellas Pharma US Inc$650
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$11,38498%
  • Education$2892%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,673 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,098
Medicare patients
12
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide70$87,554
RybelsusSemaglutide39$50,898
OzempicSemaglutide32$48,107
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$48,006
FarxigaDapagliflozin Propanediol40$38,251
EliquisApixaban27$33,680
TrulicityDulaglutide19$30,290
VraylarCariprazine Hcl20$29,542
JardianceEmpagliflozin33$27,273
Nurtec OdtRimegepant Sulfate11$24,192
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$16,925
JanuviaSitagliptin Phosphate19$15,446
Xigduo XrDapaglifloz Propaned/Metformin22$14,452
XareltoRivaroxaban15$14,429
Soliqua 100-33Insulin Glargine/Lixisenatide19$14,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$631$117,84489 claims
Novo NordiskRybelsus, Ozempic$1,244$99,00571 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,268$58,70674 claims
PfizerEliquis, Nurtec Odt$374$57,87338 claims
GSKTrelegy Ellipta, Breo Ellipta$673$55,55377 claims
Boehringer IngelheimJardiance, Glyxambi$246$34,01744 claims
AbbVieVraylar$1,422$29,54220 claims
MerckJanuvia, Belsomra$264$26,92243 claims
Johnson & JohnsonXarelto$421$14,42915 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$233$14,20819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in China Grove

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →